Biofrontera (NASDAQ:BFRI) Posts Earnings Results

Biofrontera (NASDAQ:BFRI) issued its quarterly earnings results on Friday. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.31), FiscalAI reports. The business had revenue of $9.07 million for the quarter, compared to analysts’ expectations of $8.50 million. Biofrontera had a negative return on equity of 145.81% and a negative net margin of 13.78%.

Here are the key takeaways from Biofrontera’s conference call:

• Positive Sentiment: FDA approval of Ameluz for superficial basal cell carcinoma gives Biofrontera a second U.S. indication and a non-surgical treatment option using lamps already in dermatology offices. The company expects a full commercial launch in the first quarter of 2027.
• Positive Sentiment: U.S. Customs cleared the redesigned RhodoLED XL-C from the ITC exclusion order, and Biofrontera says remediation has reduced the share of Ameluz sales affected by the order from about 25% to 10%. The company expects field remediation to be substantially complete by the end of the second quarter of 2027, though appeals remain pending.
• Positive Sentiment: Third-quarter revenue rose 29.8% year over year to $9.1 million, with Ameluz tube volume up about 23%; gross margin improved to 74.4% from 70.7%. Management cautioned that much of the volume growth reflected orders brought forward ahead of the ITC order taking effect.
• Positive Sentiment: Biofrontera submitted an application to expand Ameluz use to actinic keratosis on the extremities, neck, and trunk, with an FDA decision date of August 5, 2027. The company says approval could extend treatment to larger body areas using its existing lamps and sales force.
• Negative Sentiment: The company reported $3.2 million in cash at quarter-end and disclosed substantial doubt about its ability to continue as a going concern for at least 12 months. Its mitigation plans include revenue growth, a working credit line, a conditional $1 million divestiture milestone, and potential additional capital; management said these plans have not alleviated the doubt, and the company does not currently meet Nasdaq’s minimum stockholders’ equity requirement.

Biofrontera Trading Down 23.2%

Shares of BFRI stock traded down $0.21 on Friday, reaching $0.71. 690,195 shares of the stock were exchanged, compared to its average volume of 391,641. The stock has a market cap of $10.56 million, a P/E ratio of -1.58 and a beta of 0.88. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.78. The firm has a 50 day moving average of $1.04 and a two-hundred day moving average of $1.03. Biofrontera has a 1-year low of $0.55 and a 1-year high of $1.66.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on BFRI shares. Wall Street Zen downgraded Biofrontera from a “buy” rating to a “hold” rating in a research report on Sunday, September 20th. Zacks Research upgraded Biofrontera from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Biofrontera in a research note on Tuesday, October 13th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Biofrontera currently has a consensus rating of “Hold”.

Biofrontera Company Profile

Biofrontera Inc. (NASDAQ:BFRI) is a specialty pharmaceutical company focused on developing and commercializing prescription dermatology products, with an emphasis on treatments for precancerous and cancerous skin conditions. The company primarily serves the U.S. dermatology market through a commercial organization that supports physicians and other healthcare providers. Biofrontera’s principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, a prescription medication used with photodynamic therapy to treat actinic keratoses.